Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $37.9286.

GMAB has been the topic of a number of recent research reports. HC Wainwright decreased their price objective on Genmab A/S from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Thursday, April 30th. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Guggenheim dropped their price target on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Finally, BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd.

Genmab A/S Stock Up 1.3%

Shares of GMAB opened at $25.61 on Tuesday. The firm has a market capitalization of $15.97 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 1.50 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The business’s fifty day moving average price is $26.44 and its two-hundred day moving average price is $28.95. Genmab A/S has a 52 week low of $20.23 and a 52 week high of $35.43.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of GMAB. Personal CFO Solutions LLC increased its position in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after buying an additional 386 shares during the period. Founders Capital Management grew its holdings in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Parallel Advisors LLC grew its holdings in Genmab A/S by 11.3% in the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the period. CWM LLC grew its holdings in Genmab A/S by 18.8% in the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after purchasing an additional 433 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.